Long-term survival data of patients with limited disease small cell lung cancer: a retrospective analysis.

Abstract

INTRODUCTION:

In patients with limited disease small cell lung cancer (LD-SCLC) treated with concurrent chemoradiotherapy (CCRT), long-term survival data have not been fully evaluated. Moreover, the association between long-term prognosis and prognostic factors has not been sufficiently investigated.

METHODS:

In this retrospective study, we evaluated the efficacy of CCRT in 120 patients with LD-SCLC with a plan for curative CRT using concurrent accelerated hyperfractionated radiotherapy.

RESULTS:

The patients had a median age of 65.5 years, predominantly male (73%), and had clinical stage III disease (80%). The median follow-up time for overall survival (OS) was 72.2 months, median OS was 42.5 months, and the 3-year and 5-year survival rates were 52.4% and 41.8%, respectively. The median progression-free survival (PFS) was 12.5 months, and the 3-year and 5-year PFS rates were 37.6% and 33.6%, respectively. The 5-year OS rates of patients who achieved PFS at each time point were 70.9%, 83.6%, and 91.9% at 12, 24, and 36 months, respectively. The gradual increase in the 5-year OS rate following PFS extension and initial depression of the Kaplan-Meier curve showed disease progression frequently occurred in the first 2 years after initiation of CCRT. The Cox proportional hazards model showed no significant factors correlated with long-term survival through univariate and multivariate analyses. Although the prognostic factors associated with long-term prognosis in LD-SCLC were not identified, the 5-year survival rate was 41.8%, and among patients without disease progression at 2 years, the 5-year survival rate was 83.6%.

CONCLUSION:

These data suggested that the prognosis of patients with LD-SCLC was improving.

• Authors: Kosei Doshita, Hirotsugu Kenmotsu, Shota Omori, Yuya Tabuchi, Takanori Kawabata, Hiroaki Kodama, Naoya Nishioka, Eriko Miyawaki, Yuko Iida, Taichi Miyawaki, Nobuaki Mamesaya, Haruki Kobayashi, Ryo Ko, Kazushige Wakuda, Akira Ono, Tateaki Naito, Haruyasu Murakami, Keita Mori, Hideyuki Harada, Takeshi Kaneko, Toshiaki Takahashi
• Journal: Investigational new drugs (Invest New Drugs) Vol. 40 Issue 2 Pg. 411-419 (04 2022) ISSN: 1573-0646 [Electronic] United States
• PMID: 34716848 (Publication Type: Journal Article)
• Copyright: © 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Topics

• Aged
• Chemoradiotherapy
• Disease Progression
• Humans
• Lung Neoplasms (drug therapy)
• Male
• Neoplasm Staging
• Prognosis
• Retrospective Studies
• Small Cell Lung Carcinoma (drug therapy)
• Survival Rate
• Treatment Outcome